| Ytd | 3.10% | |
| 1y | 28.73% |
| Open | Prev Close | 4.66 | Low | High | Mkt Cap | 1.05B | |||
| Vol | 0.00 | Avg Vol | 1.17M | EPS | 0.67 | P/E | 6.96 | Forward P/E | -7.07 |
| Beta | 1.77 | Short Ratio | 1.35 | Inst. Own | 10.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 4.97 | 200-d Avg | 4.85 | 1yr Est | 5.41 |
CVAC News
German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Mode
CureVac N.V. (NASDAQ: CVAC - Get Free Report) has earned a consensus rating of "Hold" from the six r
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, represen
CureVac N.V. ( CVAC ) Shareholder/Analyst Call November 25, 2025 8:00 AM EST Company Participants Me
TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureV
CureVac N.V. (NASDAQ: CVAC - Get Free Report) has received a consensus rating of "Hold" from the six
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction annou
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech,
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Busin
GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent disp
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a p
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is invest
U.S. equities were mixed and little changed at midday as another key measure of inflation, the Produ
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (B
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA va
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
During Thursday's session, 406 companies made new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.